A phase II prospective study of gemcitabine and platin-based combination as first-line chemotherapy for metastatic Bellini duct carcinoma patients. Results of GETUG study

Stéphane Culine(Hôpital Saint-Louis), F. Rolland(Institut de Cancérologie de l'Ouest), Frank Priou, Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Frédérique Rousseau(Roche (France)), Eugéniu Banu(Hôpital Européen), Denis Langlois(Roche (France)), A. Banu, Brigitte Duclos(Roche (France))

Journal of Clinical Oncology

June 1, 2005

10.1200/jco.2005.23.16_suppl.4543

Cited by 3

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

|The Lancet|2017|1.4k

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2021|645

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

|Nature|2021|603

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal

|Cell|2018|565

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

|The Lancet Oncology|2021|411